Logo image of ACB

AURORA CANNABIS INC (ACB) Stock Fundamental Analysis

NASDAQ:ACB - Nasdaq - CA05156X8504 - Common Stock - Currency: USD

4.9  +0.19 (+4.03%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ACB. ACB was compared to 198 industry peers in the Pharmaceuticals industry. ACB may be in some trouble as it scores bad on both profitability and health. ACB is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ACB had positive earnings in the past year.
In the past year ACB has reported a negative cash flow from operations.
In the past 5 years ACB always reported negative net income.
ACB had a negative operating cash flow in each of the past 5 years.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1B -2B -3B

1.2 Ratios

The Return On Assets of ACB (1.44%) is better than 84.85% of its industry peers.
ACB has a Return On Equity of 2.18%. This is amongst the best in the industry. ACB outperforms 84.34% of its industry peers.
Industry RankSector Rank
ROA 1.44%
ROE 2.18%
ROIC N/A
ROA(3y)-64.28%
ROA(5y)-63.23%
ROE(3y)-101.76%
ROE(5y)-92.93%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

ACB's Profit Margin of 3.90% is amongst the best of the industry. ACB outperforms 84.85% of its industry peers.
Looking at the Gross Margin, with a value of 3.82%, ACB is in line with its industry, outperforming 47.98% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 3.9%
GM 3.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
ACB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ACB has been reduced compared to a year ago.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -8.90, we must say that ACB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.90, ACB is doing worse than 70.71% of the companies in the same industry.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ACB has a Debt to Equity ratio (0.07) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -8.9
ROIC/WACCN/A
WACC8.55%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

ACB has a Current Ratio of 3.30. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ACB (3.30) is comparable to the rest of the industry.
ACB has a Quick Ratio of 1.60. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
ACB's Quick ratio of 1.60 is on the low side compared to the rest of the industry. ACB is outperformed by 62.12% of its industry peers.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 1.6
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 113.32% over the past year.
Looking at the last year, ACB shows a quite strong growth in Revenue. The Revenue has grown by 19.92% in the last year.
Measured over the past years, ACB shows a very strong growth in Revenue. The Revenue has been growing by 37.40% on average per year.
EPS 1Y (TTM)113.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216%
Revenue 1Y (TTM)19.92%
Revenue growth 3Y-1.04%
Revenue growth 5Y37.4%
Sales Q2Q%36.91%

3.2 Future

Based on estimates for the next years, ACB will show a very strong growth in Earnings Per Share. The EPS will grow by 30.94% on average per year.
Based on estimates for the next years, ACB will show a quite strong growth in Revenue. The Revenue will grow by 13.75% on average per year.
EPS Next Y84.56%
EPS Next 2Y55.4%
EPS Next 3Y39.53%
EPS Next 5Y30.94%
Revenue Next Year25.65%
Revenue Next 2Y19.13%
Revenue Next 3Y15.07%
Revenue Next 5Y13.75%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 30.63, ACB can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ACB indicates a rather cheap valuation: ACB is cheaper than 80.81% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.92, ACB is valued at the same level.
The Price/Forward Earnings ratio is 20.01, which indicates a rather expensive current valuation of ACB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACB indicates a rather cheap valuation: ACB is cheaper than 81.31% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.65, ACB is valued at the same level.
Industry RankSector Rank
PE 30.63
Fwd PE 20.01
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ACB's earnings are expected to grow with 39.53% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y55.4%
EPS Next 3Y39.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURORA CANNABIS INC

NASDAQ:ACB (4/25/2025, 1:06:15 PM)

4.9

+0.19 (+4.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2025-02-05/bmo
Earnings (Next)06-18 2025-06-18/amc
Inst Owners13.84%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap268.81M
Analysts74
Price Target7.32 (49.39%)
Short Float %7.91%
Short Ratio3.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2191.63%
Min EPS beat(2)-110.8%
Max EPS beat(2)4494.06%
EPS beat(4)2
Avg EPS beat(4)1134.64%
Min EPS beat(4)-110.8%
Max EPS beat(4)4494.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.22%
Min Revenue beat(2)13.79%
Max Revenue beat(2)14.66%
Revenue beat(4)3
Avg Revenue beat(4)7.53%
Min Revenue beat(4)-5.3%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)5.79%
Revenue beat(12)6
Avg Revenue beat(12)2.25%
Revenue beat(16)8
Avg Revenue beat(16)1.88%
PT rev (1m)0.7%
PT rev (3m)12.36%
EPS NQ rev (1m)-11.11%
EPS NQ rev (3m)52.38%
EPS NY rev (1m)88.99%
EPS NY rev (3m)85.85%
Revenue NQ rev (1m)-1.16%
Revenue NQ rev (3m)10.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.89%
Valuation
Industry RankSector Rank
PE 30.63
Fwd PE 20.01
P/S 1.16
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)0.16
EY3.27%
EPS(NY)0.24
Fwd EY5%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS4.21
BVpS7.53
TBVpS6.39
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.44%
ROE 2.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3.9%
GM 3.82%
FCFM N/A
ROA(3y)-64.28%
ROA(5y)-63.23%
ROE(3y)-101.76%
ROE(5y)-92.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.17%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 1.6
Altman-Z -8.9
F-Score6
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)46.6%
Cap/Depr(5y)183.64%
Cap/Sales(3y)14.16%
Cap/Sales(5y)67.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)113.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216%
EPS Next Y84.56%
EPS Next 2Y55.4%
EPS Next 3Y39.53%
EPS Next 5Y30.94%
Revenue 1Y (TTM)19.92%
Revenue growth 3Y-1.04%
Revenue growth 5Y37.4%
Sales Q2Q%36.91%
Revenue Next Year25.65%
Revenue Next 2Y19.13%
Revenue Next 3Y15.07%
Revenue Next 5Y13.75%
EBIT growth 1Y7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year210.19%
EBIT Next 3Y52.94%
EBIT Next 5Y31.71%
FCF growth 1Y80.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.36%
OCF growth 3YN/A
OCF growth 5YN/A